IP Library Granted Patent US 7,704,949
Granted Patent B2
US 7,704,949 · App. 11/466,979 · Granted Apr 27, 2010

Kallikrein-inhibitor therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,704,949
App. No.
11/466,979
Granted
Apr 27, 2010
Kind
B2
Abstract

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Claims (17)

1. A method for reducing reperfusion injury in a patient, the method comprising:

administering to the patient a composition comprising an inhibitor of plasma kallikrein, in an amount effective to reduce neurocognitive defects due to reperfusion injury, wherein the inhibitor of plasma kallikrein comprises a polypeptide that comprises the amino acid sequence of SEQ ID NO: 57.

2. The method of claim 1 , wherein the reperfusion injury is reperfusion injury associated with cerebral ischemia.

3. The method of claim 2 , wherein the cerebral ischemia is a stroke.

4. The method of claim 3 , wherein the stroke is selected from the group consisting of an embolism associated stroke, a thrombus-associated stroke, a thromboembolitic stroke and a hemorrhage-associated stroke.

5. The method of claim 3 , wherein the stroke is an embolism-associated stroke.

6. The method of claim 3 , wherein the stroke is a thrombus-associated stroke.

7. The method of claim 6 , wherein the thrombus-associated stroke is a perioperative stroke.

8. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

9. The method of claim 1 , wherein the inhibitor of plasma kallikrein is administered parenterally.

10. The method of claim 9 , wherein the inhibitor of plasma kallikrein is administered intravenously.

11. The method of claim 9 , wherein the inhibitor of plasma kallikrein is administered intraperitoneally.

12. The method of claim 1 , wherein the inhibitor of plasma kallikrein is conjugated to a water soluble polymer.

13. The method of claim 12 , wherein the water soluble polymer is a hydrophilic polyvinyl polymer or polymers.

14. The method of claim 13 , wherein the hydrophilic polyvinyl polymer is selected from the group consisting of polyvinylalcohol and polyvinylpyrrolidone.

15. The method of claim 13 , wherein the hydrophilic polyvinyl polymer is selected from the group consisting of polyalkylene oxide homopolymers, polypropylene glycols, polyoxyethylenated polyols, and copolymers thereof.

16. The method of claim 13 , wherein the water soluble polymer is polyethylene glycol (PEG).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →